Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Review uri icon



  • Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune responses can regress tumors. However, this only occurs in a fraction of patients. Incorporating these therapies in more powerful combinations is thus a logical next step. Here, we review functional roles of immune checkpoints and molecular determinants of checkpoint-blockade clinical activity. Limited-size T cell-infiltrated tumors, differing substantially from "self," generally respond to checkpoint blockade. Therefore, we propose that reducing tumor burden and increasing tumor immunogenicity are key factors to improve immunotherapy. Lastly, we outline criteria to select proper immunotherapy combination partners and highlight the importance of activity biomarkers for timely treatment optimization.

publication date

  • April 9, 2018



  • Antibodies, Blocking
  • Combined Modality Therapy
  • Neoplasms


PubMed Central ID

  • PMC5896787

Scopus Document Identifier

  • 85044272999

Digital Object Identifier (DOI)

  • 10.1016/j.ccell.2018.03.005

PubMed ID

  • 29634946

Additional Document Info


  • 33


  • 4